Provectus Pharmatech, Inc

Uti Limited Partnership

Photogen, Inc.

Pfizer Corporation

Ut-battelle, Inc.

Xantech Pharmaceuticals, Inc.

Provectus Pharmaceuticals, Inc.

Other

Martin Marietta Energy Systems, Inc.

Provectus Devicetech, Inc.

The Rockefeller University

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Lockheed Martin Energy Research Corporation

Lockheed Martin Energy Systems, Inc.

University of Calgary

Eric A Wachter

H Craig Dees

Walter G Fisher

Timothy C Scott

Jamie Singer

John T Smolik

Aru Narendran

Thomas George Thundat

Satbir Thakur

Lucy Swift

Chunfen Zhang

Mohit Jain

Dominic Rodrigues

Craig J Eagle

Marlon Lutz

Kevin Babiak

Edward V Pershing

Bruce Horowitz

J Kenneth Davis

Robert J Warmack

Sahadeva Reddy Damireddi

Shari Pilon-Thomas

Amod A Sarnaik

Hao Liu

J Robert Durrwachter

James G Krueger

Sandra Garcet

Tanya Trippett

John Smolik

Craig H Dees

A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C-Calkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

Halogenated xanthene composition and method for treating hematologic cancers

A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

Composition and method for oral treatment of leukemia

A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.

Uses of halogenated xanthenes in oncology and virology

A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-&#x3b1;, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.

Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

A cancer immunotherapy method is disclosed in which 'induced immune anticancer agents' are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100&#xb0; C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.

Process for the synthesis of 4,5,6,7-tetrachloro-3',6&#x2032;-dihydroxy-2&#x2032;,4&#x2032;,5&#x2032;,7&#x2032;-tetraiodo-3H-spiro[isobenzofuran-1,9&#x2032;-xanthen]-3-one(Rose Bengal) and related xanthenes

Process for the synthesis of 4,5,6,7-tetrachloro-3',6&#x2032;-dihydroxy-2&#x2032;, 4&#x2032;, 5&#x2032;7&#x2032;-tetraiodo-3H-spiro[isobenzofuran-1,9&#x2032;-xanthen]-3-one (Rose Bengal) and related xanthenes

Growing community of inventors

Oak Ridge, TN, United States of America

Eric A Wachter